Saliha Yilmaz

Critic
DISC Type : C

Director, Data Science at Agios Pharmaceuticals

Cambridge, Massachusetts, United States

Overview

Saliha Yilmaz is the Director of Data Science at Agios Pharmaceuticals, where she leads bioinformatics and enables AI integration. Her expertise lies in applying data-driven insights from genomics and transcriptomics to advance precision medicine. She holds a Ph. D. from Universite de Lorraine and a SciPhD certification focused on translating science into business applications.

Her career has been dedicated to investigating the genetic and molecular components of human diseases, contributing significant discoveries in rare neurological and skeletal disorders. Her research background spans work at Yale University and Kings College London before moving into the pharmaceutical industry.

Unique fact: Salihas Ph. D. work focused on the genetics of Aicardi Syndrome, a rare and complex neurological disease.

Personality Overview

Information Seeker

Negotiator

Objective Thinker

They like to take decisions independently and do not seek others' support often.  It is very likely that they will negotiate pricing or other important terms. Unless the value is proven by data, they are unlikely to value fancy features.

Topics They Care About

AI in Research
Identifies as an "AI enabler" and is passionate about leveraging artificial intelligence to augment pharmaceutical research capabilities and drive new discoveries.
Rare Disease Genetics
Has an extensive publication history and research background in the genetics of rare conditions, including skeletal dysplasias, Aicardi Syndrome, and Pyruvate Kinase Deficiency.
Precision Medicine
Her work focuses on using advanced genomics and transcriptomics to unlock new pathways and develop targeted, data-driven medical treatments.

Media Appearances

Saliha has no verified media appearances

Work History

10-2023
Director, Data Science at Agios Pharmaceuticals
5-2021 - 10-2023
Associate Director, Data Science at Agios Pharmaceuticals
7-2019 - 5-2021
Principal Scientist, Genetic Epidemiology at Rhythm Pharmaceuticals Inc.
8-2017 - 7-2019
Research Geneticist at Genuity Science
4-2010 - 8-2017
Associate Research Scientist at Yale University School of Medicine

Education

2003 - 2007
Doctor of Philosophy (Ph.D.) from Universite de Lorraine
2002 - 2003
Master's Degree from Universite de Lorraine

More Information

Social Presence :

Prographics :

Exp : 23 Location : Cambridge, Massachusetts, United States Job Level : Mid-senior Designation : Director, Data Science at Agios Pharmaceuticals
URL has been copied!

Insights For Selling To Saliha

During A Call Or A Meeting

DO's

  • If you can, show them industry reports or analyst comments instead of sharing anecdotal stories
  • Don’t forget to mention how you compare to competition on both features and pricing
  • Be formal and objective, they will appreciate it more

DONT's

  • Avoid phrases like ‘trust me’, ‘others just love’ etc.
  • Don’t try to give too many examples of other users, they like to make their own decisions
  • Do not use very emotional or colorful language

When Cold Calling

When Writing An Email

While Negotiating & Closing

    The secret to closing fast with Saliha is

  • Proof of ROI, low pricing and objective proof points are the important factors for them.
  • Will you ever get a clear answer from Saliha

  • They do not mind saying no if they believe that it is the right decision.

Insights For Deal Planning

    How fast (or slow) will Saliha move?

  • Their decision-making is neither very fast nor very slow, they are somewhere in between.
  • Can Saliha take some risk or not?

  • They can take risks if their analysis shows that it would be worth it.

You And Saliha

Personality Compatibility


Other Agios Pharmaceuticals Employees

Explore more public profiles from related professionals at the same organization.

More Profiles

Discover additional public profiles from our index.

Search more profiles

Looking for someone else? Search here for anyone.

Or visit Humantic AI to know more.